Acerus Pharmaceuticals (TRLPF) Stock Price, News & Analysis

Company Overview

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.

Key Stats

• Today's Range: $0.22 to $0.22
• 50-Day Range: $0.22 to $0.22
• 52-Week Range: $0.08 to $0.34
• Volume: N/A
• Average Volume: 5,474 shs
• Market Capitalization: $56.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TRLPF Stock Analysis - Frequently Asked Questions

How have TRLPF shares performed this year?

Acerus Pharmaceuticals' stock was trading at $0.22 on January 1st, 2025. Since then, TRLPF stock has increased by 0.0% and is now trading at $0.22.
View the best growth stocks for 2025 here.

How were Acerus Pharmaceuticals' earnings last quarter?

Acerus Pharmaceuticals Co. (OTCMKTS:TRLPF) released its quarterly earnings results on Monday, November, 5th. The specialty pharmaceutical company reported ($0.01) EPS for the quarter, hitting analysts' consensus estimates of ($0.01). The specialty pharmaceutical company earned $1.58 million during the quarter. Acerus Pharmaceuticals had a negative net margin of 254.66% and a negative trailing twelve-month return on equity of 346.72%.

How do I buy shares of Acerus Pharmaceuticals?

Shares of TRLPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 11/05/2018
• Today: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:TRLPF
• CIK: N/A
• Web: www.aceruspharma.com
• Phone: 416-679-0771
• Fax: N/A
• Employees: 29
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.79 million
• Net Margins: -254.66%
• Pretax Margin: N/A
• Return on Equity: -346.72%
• Return on Assets: -94.54%

Debt

• Debt-to-Equity Ratio: 0.64
• Current Ratio: 1.35
• Quick Ratio: 0.90

Sales & Book Value

• Annual Sales: $7.38 million
• Price / Sales: 7.71
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 258,615,000
• Free Float: N/A
• Market Cap: $56.90 million
• Optionable: Not Optionable
• Beta: 2.60